Zhang Li

Ms. Zhang Li


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
ALArian Lundberg
Arian Lundberg
MZMeng Zhang
Meng Zhang
RARahul Aggarwal
Rahul Aggarwal
HLHaolong Li
Haolong Li
ZLZhang Li
Zhang Li
DQDavid A. Quigley
David A. Quigley
Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation androgen receptor (AR)–targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration-resistant prostate cancer (mCRPC), defined by AR and neuroendocrine (NE) markers. Molecular drivers of double-negative (AR−/NE−) mCRPC are poorly defined. In this study, we comprehensively characterized treatment-emergent mCRPC by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing from 210 tumors. AR−/NE− tumors were clinically and molecularly distinct from other mCRPC subtypes, with the shortest survival, amplification of the chromatin remodeler CHD7, and PTEN loss. Methylation changes in CHD7 candidate enhancers were linked to elevated CHD7 expression in AR−/NE+ tumors. Genome-wide methylation analysis nominated Krüppel-like factor 5 (KLF5) as a driver of the AR−/NE− phenotype, and KLF5 activity was linked to RB1 loss. These observations reveal the aggressiveness of AR−/NE− mCRPC and could facilitate the identification of therapeutic targets in this highly aggressive disease. Significance: Comprehensive characterization of the five subtypes of metastatic castration-resistant prostate cancer identified transcription factors that drive each subtype and showed that the double-negative subtype has the worst prognosis.

11 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EBErin Lynn Van Blarigan
Erin Lynn Van Blarigan
HCHilary Chan
Hilary Chan
KLKatherine Van Loon
Katherine Van Loon
SKStacey Ann Kenfield
Stacey Ann Kenfield
JCJune M. Chan
June M. Chan
AVAlan P. Venook
Alan P. Venook
Over 1.3 million people live with colorectal cancer in the United States. Physical activity is associated with lower risk of colorectal cancer recurrence and mortality. Interventions are needed to increase physical activity in colorectal cancer survivors. We conducted a 2-arm non-blinded pilot randomized controlled trial at the University of California, San Francisco among 42 individuals who had completed curative-intent treatment for colorectal cancer to determine the feasibility and acceptability of a 12-week (84 days) physical activity intervention using a Fitbit Flex™ and daily text messages. Participants were randomized 1:1 to receive the intervention with print educational materials or print educational materials alone. We explored the impact of the intervention versus usual care on physical activity using ActiGraph GT3X+ accelerometers pre−/post-intervention. We screened 406 individuals and randomized 42 to intervention (n = 21) or control (n = 21) groups. During the 12-week study, the intervention arm wore their Fitbits a median of 74 days [88% of days in study period, interquartile range: 23–83 days] and responded to a median of 34 (out of 46) text messages that asked for a reply (interquartile range: 13–38 text messages). Among the 16 intervention participants who completed the feedback survey, the majority (88%) reported that the intervention motivated them to exercise and that they were satisfied with their experience. No statistically significant difference in change in moderate-to-vigorous physical activity was found from baseline to 12 weeks between arms. A 12-week physical activity intervention with a Fitbit and text messages was feasible and acceptable among colorectal cancer patients after curative treatment. Larger studies are needed to determine whether the intervention increases physical activity. Clinicaltrials.gov Identifier NCT02966054 . Registered 17 November 2016, retrospectively registered.

1 March 2005 in Molecular Brain Research
Verified
Journal Article
Closed access
MSMika Shimoji
Mika Shimoji
ZLZhang Li
Zhang Li
AMAllen S. Mandir
Allen S. Mandir
VDValina L. Dawson
Valina L. Dawson
Ted DawsonTed Dawson
Ted Dawson

1 April 2014 in Analytical Biochemistry
Verified
Journal Article
Closed access
XLXiao-Fei Li
Xiao-Fei Li
YWYuhua Wu
Yuhua Wu
ZLZhang Li
Zhang Li
YCYinglong Cao
Yinglong Cao
YLYunjing Li
Yunjing Li
WGWu Gang
Wu Gang

14 March 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ABAnil Bidkar
Anil Bidkar
SWSinan Wang
Sinan Wang
Kondapa Naidu BobbaKondapa Naidu Bobba
Kondapa Naidu Bobba
ECEmily Chan
Emily Chan
SBScott Bidlingmaier
Scott Bidlingmaier
RFRobert Flavell
Robert Flavell
Purpose: Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression in prostate cancer and developed an antibody–drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46 epitope. Here, we present the preparation, preclinical efficacy, and toxicity evaluation of [225Ac]DOTA-YS5, a radioimmunotherapy agent based on the YS5 antibody. Experimental Design: [225Ac]DOTA-YS5 was developed, and its therapeutic efficiency was tested on cell-derived (22Rv1, DU145), and patient-derived (LTL-545, LTL484) prostate cancer xenograft models. Biodistribution studies were carried out on 22Rv1 tumor xenograft models to confirm the targeting efficacy. Toxicity analysis of the [225Ac]DOTA-YS5 was carried out on nu/nu mice to study short-term (acute) and long-term (chronic) toxicity. Results: Biodistribution study shows that [225Ac]DOTA-YS5 agent delivers high levels of radiation to the tumor tissue (11.64% ± 1.37%ID/g, 28.58% ± 10.88%ID/g, 29.35% ± 7.76%ID/g, and 31.78% ± 5.89%ID/g at 24, 96, 168, and 408 hours, respectively), compared with the healthy organs. [225Ac]DOTA-YS5 suppressed tumor size and prolonged survival in cell line–derived and patient-derived xenograft models. Toxicity analysis revealed that the 0.5 μCi activity levels showed toxicity to the kidneys, likely due to redistribution of daughter isotope 213Bi. Conclusions: [225Ac]DOTA-YS5 suppressed the growth of cell-derived and patient-derived xenografts, including prostate-specific membrane antigen–positive and prostate-specific membrane antigen–deficient models. Overall, this preclinical study confirms that [225Ac]DOTA-YS5 is a highly effective treatment and suggests feasibility for clinical translation of CD46-targeted radioligand therapy in prostate cancer.

1 June 2011 in Clinical Immunology
Verified
Journal Article
Closed access
NTNingwen Tai
Ningwen Tai
HYHisafumi Yasuda
Hisafumi Yasuda
YXYufei Xiang
Yufei Xiang
ZLZhang Li
Zhang Li
DRDaniel Rodriguez-Pinto
Daniel Rodriguez-Pinto
LWLi Wen
Li Wen